Rani Therapeutics Holdings reported revenue of $1.71M and net income of -$8.42M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 49.00M | 53.68M | 49.16M | 49.16M | 49.36M | 49.41M | 49.49M | 49.63M | 49.99M | 50.15M | 50.41M | 50.60M | 53.92M | 57.40M | 57.54M | 63.21M | 71.91M | 121.59M | 180.00M | 187.17M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 1.03M | 0.17M | 1.46M | 1.71M | 1.71M | ||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 11.96M | 7.42M | 7.59M | 9.53M | 9.10M | 10.39M | 9.71M | 11.09M | 11.22M | 7.61M | 7.59M | 6.12M | 6.17M | 6.81M | 6.57M | 5.50M | 3.22M | 4.91M | 5.16M | 5.02M | |||||
| Selling, General & AdministrativeSG&A | 15.82M | 5.95M | 6.19M | 6.32M | 7.24M | 7.10M | 6.80M | 7.21M | 6.63M | 5.83M | 6.45M | 6.41M | 5.63M | 5.46M | 5.62M | 5.00M | 4.04M | 5.09M | 4.89M | 5.52M | |||||
| Other Operating ExpensesOther Opex | 3.71M | ||||||||||||||||||||||||
| Operating ExpensesOpex | 27.78M | 13.36M | 13.78M | 15.85M | 16.34M | 17.48M | 16.52M | 18.29M | 17.86M | 13.43M | 14.03M | 12.52M | 11.80M | 15.99M | 12.19M | 10.51M | 7.26M | 10.00M | 10.05M | 10.54M | |||||
| Operating IncomeOp. Inc | -27.78M | -13.36M | -13.78M | -15.85M | -16.34M | -17.48M | -16.52M | -18.29M | -17.86M | -13.43M | -14.03M | -12.52M | -11.80M | -14.96M | -12.01M | -10.51M | -7.26M | -8.54M | -8.34M | -8.83M | |||||
| EBIT | -27.78M | -13.36M | -13.78M | -15.85M | -16.34M | -17.48M | -16.52M | -18.29M | -17.86M | -13.43M | -14.03M | -12.52M | -11.80M | -14.96M | -12.01M | -10.51M | -7.26M | -8.54M | -8.34M | -8.83M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.11M | -0.00M | 0.35M | 0.72M | 1.21M | 1.27M | 1.32M | 1.30M | 1.29M | 1.28M | 1.34M | 1.12M | 0.94M | 0.88M | 0.72M | 0.35M | 0.09M | 0.01M | |||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.02M | 0.01M | 0.04M | 0.38M | 0.82M | 0.89M | 0.90M | 0.84M | 0.68M | 0.55M | 0.44M | 0.41M | 0.36M | 0.22M | 0.16M | 0.07M | 0.38M | 0.41M | 0.41M | |||||
| Other Non Operating IncomeOther Non Op Inc. | -0.70M | 1.40M | |||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||
| EBT | -28.66M | -13.35M | -13.77M | -15.81M | -16.32M | -17.38M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -8.50M | -8.02M | -8.42M | |||||
| Tax ProvisionsTaxes | 0.04M | -0.04M | 0.06M | 0.15M | -0.11M | -0.01M | |||||||||||||||||||
| Profit After TaxPAT | -28.70M | -13.30M | -13.83M | -15.97M | -16.21M | -17.34M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -9.10M | -8.02M | -8.42M | |||||
| Income from Non-Controlling InterestsInc. Minority | -25.56M | -8.12M | -7.61M | -8.34M | -8.25M | -8.56M | -8.46M | -9.41M | -9.13M | -6.96M | -7.30M | -6.56M | -5.94M | -6.78M | -5.47M | -4.53M | -2.50M | 1.23M | -0.98M | -1.03M | |||||
| Income from Continuing OperationsIncome (Continuing) | -28.70M | -13.30M | -13.83M | -15.97M | -16.21M | -17.37M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -8.50M | -8.02M | -8.42M | |||||
| Consolidated Net IncomeConsol Net Inc. | -28.70M | -13.30M | -13.83M | -15.97M | -16.21M | -17.37M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -8.50M | -8.02M | -8.42M | |||||
| Income towards Parent CompanyParent Net Inc | -28.70M | -13.30M | -13.83M | -15.97M | -16.21M | -17.37M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -8.50M | -8.02M | -8.42M | |||||
| Net Income towards Common StockholdersNet Income | -28.70M | -13.30M | -13.83M | -15.97M | -16.21M | -17.37M | -16.83M | -18.66M | -18.33M | -14.05M | -14.78M | -13.36M | -12.72M | -15.72M | -12.74M | -11.22M | -7.91M | -8.50M | -8.02M | -8.42M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -1.48 | -0.68 | -0.65 | -0.66 | -0.66 | -0.73 | -0.67 | -0.74 | -0.72 | -0.55 | -0.57 | -0.51 | -0.44 | -0.55 | -0.38 | -0.31 | -0.17 | -0.13 | -0.04 | -0.04 | |||||
| EPS (Diluted) | -1.48 | -0.68 | -0.65 | -0.66 | -0.66 | -0.73 | -0.67 | -0.74 | -0.72 | -0.55 | -0.57 | -0.51 | -0.44 | -0.55 | -0.38 | -0.31 | -0.17 | -0.13 | -0.04 | -0.04 | |||||
| Shares Outstanding | 19.44M | 19.53M | 21.41M | 24.37M | 24.47M | 23.82M | 25.24M | 25.34M | 25.55M | 25.50M | 26.03M | 26.32M | 28.84M | 28.48M | 33.44M | 36.54M | 46.44M | 66.14M | 180.00M | 187.17M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 19.44M | 19.53M | 21.41M | 24.37M | 24.47M | 23.82M | 25.24M | 25.34M | 25.55M | 25.50M | 26.03M | 26.32M | 28.84M | 28.48M | 33.44M | 36.54M | 46.44M | 66.14M | 180.00M | 187.17M | |||||
| EBITDA | -27.78M | -13.36M | -13.78M | -15.85M | -16.34M | -17.48M | -16.52M | -18.29M | -17.86M | -13.43M | -14.03M | -12.52M | -11.80M | -14.96M | -12.01M | -10.51M | -7.26M | -8.54M | -8.34M | -8.83M | |||||
| Interest ExpensesInt Expense | 0.11M | -0.00M | 0.35M | 0.72M | 1.21M | 1.27M | 1.32M | 1.30M | 1.29M | 1.28M | 1.34M | 1.12M | 0.94M | 0.88M | 0.72M | 0.35M | 0.09M | 0.01M | |||||||
| Tax Rate | -0.13 | 0.30 | -0.46 | -0.97 | 0.65 | 0.06 |